Hematologic Oncology

An investigational drug known as brentuximab vedotin (SGN-35) achieved dramatic responses in a phase II study of younger patients with relapsed or refractory Hodgkin lymphoma (HL) who had no other treatment options

There's been a flurry of activity in recent weeks when it comes to oncology drug filings at the FDA. While every application is unique, the agency is required to decide within 60 days whether a new drug application (NDA) will move forward for a full review.

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

Practicing clinicians and healthcare administrators face many challenges in treating cancer patients, including management of chemotherapy-induced anemia.

Recent statistics show lymphoid malignancies to be the fifth most common cause of cancer-related death in the United States.

Author of six bestselling books, a television and film actor, and a filmmaker; Abdul-Jabbar is gaining fame for a role he never wanted: that of a chronic myeloid leukemia (CML) patient.

Siddhartha Mukherjee, MD, discusses his book The Emperor of All Maladies.

The FDA approved Tasigna (nilotinib) as a first-line treatment for patients with newly diagnosed Philadelphia- chromosome positive (Ph ) chronic myeloid leukemia (CML), the first new drug approved for this indication in nearly a decade.

In reviewing the therapeutic category of blood modifiers, there are 3 areas of focus

Patients with cancer and comorbid type 2 diabetes have 5 times the risk of contracting listeria, a rare bacterial illness caused by eating contaminated food.

A collection of cancer statistics and facts

Final results for the complete cohort of 300 patients with chronic lymphocytic leukemia (CLL) receiving the FCR (fludarabine, cyclophosphamide, and rituximab)regimen were presented at this year%u2019s American Society of Clinical Oncology meeting.

Treatment advances focus on the potential use of Bortezomib and Lenalidomide in the front-line setting to improve patients' response rates.

Stanford University School of Medicine investigators may have discovered a new chemotherapy target for a deadly form of leukemia. A molecular signal, glycogen synthase kinase 3 (GSK3), known to regulate cell growth appears to play a %u201Cdouble agent%u201D role.

Highlights from the 50th Annual Meeting of the American Society of Hematology.